Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine

Cell

Volumn 166, Issue 1, 2016, Pages 126-139

  Briggs, Kimberly J ^a   Koivunen, Peppi ^b   Cao, Shugeng ^c,i   Backus, Keriann M ^d   Olenchock, Benjamin A ^c   Patel, Hetalben ^e   Zhang, Qing ^f   Signoretti, Sabina ^c   Gerfen, Gary J ^e   Richardson, Andrea L ^c,j   Witkiewicz, Agnieszka K ^g   Cravatt, Benjamin F ^d   Clardy, Jon ^c   Kaelin, William G ^a,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF OULU   (Finland)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

ⁱ UNIVERSITY OF HAWAII AT HILO   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYSTEINE; GLUCOSE TRANSPORTER 1; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; MESSENGER RNA; OXYGEN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN; PROTEIN BNIP3; PROTEIN EGLN1; UNCLASSIFIED DRUG; VASCULOTROPIN; AMINO ACID TRANSPORTER; EGLN1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; SLC7A11 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYDROXYLATION; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN STABILITY; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; ANIMAL; BREAST TUMOR; MCF-7 CELL LINE; METABOLISM;

AMINO ACID TRANSPORT SYSTEM Y+; ANIMALS; BREAST NEOPLASMS; CYSTEINE; GLUTAMIC ACID; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MCF-7 CELLS; MICE; PARACRINE COMMUNICATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84976907997     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.05.042     Document Type: Article

References (52)

1. Andras, I.E., Deli, M.A., Veszelka, S., Hayashi, K., Hennig, B., Toborek, M., The NMDA and AMPA/KA receptors are involved in glutamate-induced alterations of occludin expression and phosphorylation in brain endothelial cells. J. Cereb. Blood Flow Metab. 27 (2007), 1431–1443.
2. Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.P., Johnson, R.S., Bergers, G., The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4 (2003), 133–146.
3. Bos, R., van Der Hoeven, J.J., van Der Wall, E., van Der Groep, P., van Diest, P.J., Comans, E.F., Joshi, U., Semenza, G.L., Hoekstra, O.S., Lammertsma, A.A., Molthoff, C.F., Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol. 20 (2002), 379–387.
4. Chaturvedi, P., Gilkes, D.M., Wong, C.C., Kshitiz, Luo, W., Zhang, H., Wei, H., Takano, N., Schito, L., Levchenko, A., Semenza, G.L., Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Invest. 123 (2013), 189–205.
5. Chen, X., Iliopoulos, D., Zhang, Q., Tang, Q., Greenblatt, M.B., Hatziapostolou, M., Lim, E., Tam, W.L., Ni, M., Chen, Y., et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature 508 (2014), 103–107.
6. Chowdhury, R., Flashman, E., Mecinović, J., Kramer, H.B., Kessler, B.M., Frapart, Y.M., Boucher, J.L., Clifton, I.J., McDonough, M.A., Schofield, C.J., Studies on the reaction of nitric oxide with the hypoxia-inducible factor prolyl hydroxylase domain 2 (EGLN1). J. Mol. Biol. 410 (2011), 268–279.
7. Chung, H.S., Wang, S.B., Venkatraman, V., Murray, C.I., Van Eyk, J.E., Cysteine oxidative posttranslational modifications: emerging regulation in the cardiovascular system. Circ. Res. 112 (2013), 382–392.
8. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149 (2012), 1060–1072.
9. Flashman, E., Davies, S.L., Yeoh, K.K., Schofield, C.J., Investigating the dependence of the hypoxia-inducible factor hydroxylases (factor inhibiting HIF and prolyl hydroxylase domain 2) on ascorbate and other reducing agents. Biochem. J. 427 (2010), 135–142.
10. Green, J., Paget, M.S., Bacterial redox sensors. Nat. Rev. Microbiol. 2 (2004), 954–966.
11. Gross, M.I., Demo, S.D., Dennison, J.B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J.R., Laidig, G.J., Lewis, E.R., Li, J., et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13 (2014), 890–901.
12. Hirsilä, M., Koivunen, P., Xu, L., Seeley, T., Kivirikko, K.I., Myllyharju, J., Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J. 19 (2005), 1308–1310.
13. Ishii, T., Hishinuma, I., Bannai, S., Sugita, Y., Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol. J. Cell. Physiol. 107 (1981), 283–293.
14. Jacob, C., Redox signalling via the cellular thiolstat. Biochem. Soc. Trans. 39 (2011), 1247–1253.
15. Janjic, D., Wollheim, C.B., Effect of 2-mercaptoethanol on glutathione levels, cystine uptake and insulin secretion in insulin-secreting cells. Eur. J. Biochem. 210 (1992), 297–304.
16. Juva, K., Prockop, D.J., Modified procedure for the assay of H-3-or C-14-labeled hydroxyproline. Anal. Biochem. 15 (1966), 77–83.
17. Kaelin, W.G. Jr., ROS: really involved in oxygen sensing. Cell Metab. 1 (2005), 357–358.
18. Kaelin, W.G. Jr., Ratcliffe, P.J., Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30 (2008), 393–402.
19. Keith, B., Johnson, R.S., Simon, M.C., HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12 (2012), 9–22.
20. Koivunen, P., Hirsilä, M., Kivirikko, K.I., Myllyharju, J., The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. J. Biol. Chem. 281 (2006), 28712–28720.
21. Laurinavicius, A., Laurinaviciene, A., Ostapenko, V., Dasevicius, D., Jarmalaite, S., Lazutka, J., Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn. Pathol., 7, 2012, 27.
22. Lee, G., Won, H.S., Lee, Y.M., Choi, J.W., Oh, T.I., Jang, J.H., Choi, D.K., Lim, B.O., Kim, Y.J., Park, J.W., et al. Oxidative dimerization of PHD2 is responsible for its inactivation and contributes to metabolic reprogramming via HIF-1alpha activation. Sci. Rep., 6, 2016, 18928.
23. Lu, H., Dalgard, C.L., Mohyeldin, A., McFate, T., Tait, A.S., Verma, A., Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem. 280 (2005), 41928–41939.
24. Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J.W., Semenza, G.L., Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc. Natl. Acad. Sci. USA 112 (2015), E4600–E4609.
25. Makowske, M., Christensen, H.N., Contrasts in transport systems for anionic amino acids in hepatocytes and a hepatoma cell line HTC. J. Biol. Chem. 257 (1982), 5663–5670.
26. Mecinović, J., Chowdhury, R., Flashman, E., Schofield, C.J., Use of mass spectrometry to probe the nucleophilicity of cysteinyl residues of prolyl hydroxylase domain 2. Anal. Biochem. 393 (2009), 215–221.
27. Mehta, M.S., Dolfi, S.C., Bronfenbrener, R., Bilal, E., Chen, C., Moore, D., Lin, Y., Rahim, H., Aisner, S., Kersellius, R.D., et al. Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. PLoS ONE, 8, 2013, e69851.
28. Montagner, M., Enzo, E., Forcato, M., Zanconato, F., Parenti, A., Rampazzo, E., Basso, G., Leo, G., Rosato, A., Bicciato, S., et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487 (2012), 380–384.
29. Myllylä, R., Kuutti-Savolainen, E.R., Kivirikko, K.I., The role of ascorbate in the prolyl hydroxylase reaction. Biochem. Biophys. Res. Commun. 83 (1978), 441–448.
30. Narang, V.S., Pauletti, G.M., Gout, P.W., Buckley, D.J., Buckley, A.R., Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res. 23:6C (2003), 4571–4579.
31. Narang, V.S., Pauletti, G.M., Gout, P.W., Buckley, D.J., Buckley, A.R., Sulfasalazine-induced reduction of glutathione levels in breast cancer cells: enhancement of growth-inhibitory activity of Doxorubicin. Chemotherapy 53 (2007), 210–217.
32. North, W.G., Gao, G., Memoli, V.A., Pang, R.H., Lynch, L., Breast cancer expresses functional NMDA receptors. Breast Cancer Res. Treat. 122 (2010), 307–314.
33. Nytko, K.J., Maeda, N., Schläfli, P., Spielmann, P., Wenger, R.H., Stiehl, D.P., Vitamin C is dispensable for oxygen sensing in vivo. Blood 117 (2011), 5485–5493.
34. Regan Anderson, T.M., Peacock, D.L., Daniel, A.R., Hubbard, G.K., Lofgren, K.A., Girard, B.J., Schörg, A., Hoogewijs, D., Wenger, R.H., Seagroves, T.N., Lange, C.A., Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res. 73 (2013), 5810–5820.
35. Schito, L., Rey, S., Tafani, M., Zhang, H., Wong, C.C., Russo, A., Russo, M.A., Semenza, G.L., Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc. Natl. Acad. Sci. USA 109 (2012), E2707–E2716.
36. Seidlitz, E.P., Sharma, M.K., Saikali, Z., Ghert, M., Singh, G., Cancer cell lines release glutamate into the extracellular environment. Clin. Exp. Metastasis 26 (2009), 781–787.
37. Semenza, G.L., Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol. Med. 18 (2012), 534–543.
38. Sharma, M.K., Seidlitz, E.P., Singh, G., Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem. Biophys. Res. Commun. 391 (2010), 91–95.
39. Sims, B., Clarke, M., Francillion, L., Kindred, E., Hopkins, E.S., Sontheimer, H., Hypoxic preconditioning involves system Xc- regulation in mouse neural stem cells. Stem Cell Res. (Amst.) 8 (2012), 285–291.
40. Speyer, C.L., Smith, J.S., Banda, M., DeVries, J.A., Mekani, T., Gorski, D.H., Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res. Treat. 132 (2012), 565–573.
41. Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12 (2012), 564–571.
42. Stepulak, A., Rola, R., Polberg, K., Ikonomidou, C., Glutamate and its receptors in cancer. J Neural Transm (Vienna) 121 (2014), 933–944.
43. Talks, K.L., Turley, H., Gatter, K.C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., Harris, A.L., The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157 (2000), 411–421.
44. Timmerman, L.A., Holton, T., Yuneva, M., Louie, R.J., Padró, M., Daemen, A., Hu, M., Chan, D.A., Ethier, S.P., van ’t Veer, L.J., et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24 (2013), 450–465.
45. Weerapana, E., Speers, A.E., Cravatt, B.F., Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)—a general method for mapping sites of probe modification in proteomes. Nat. Protoc. 2 (2007), 1414–1425.
46. Weerapana, E., Wang, C., Simon, G.M., Richter, F., Khare, S., Dillon, M.B., Bachovchin, D.A., Mowen, K., Baker, D., Cravatt, B.F., Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468 (2010), 790–795.
47. Willard, S.S., Koochekpour, S., Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int. J. Biol. Sci. 9 (2013), 728–742.
48. Wong, C.C., Zhang, H., Gilkes, D.M., Chen, J., Wei, H., Chaturvedi, P., Hubbi, M.E., Semenza, G.L., Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J. Mol. Med. 90 (2012), 803–815.
49. Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156 (2014), 317–331.
50. Yang, Y., Yee, D., IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-. Cancer Res. 74 (2014), 2295–2305.
51. Zhang, H., Wong, C.C., Wei, H., Gilkes, D.M., Korangath, P., Chaturvedi, P., Schito, L., Chen, J., Krishnamachary, B., Winnard, P.T. Jr., et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 31 (2012), 1757–1770.
52. Zhong, H., De Marzo, A.M., Laughner, E., Lim, M., Hilton, D.A., Zagzag, D., Buechler, P., Isaacs, W.B., Semenza, G.L., Simons, J.W., Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999), 5830–5835.